Literature DB >> 19934114

Expression analysis of novel striatal-enriched genes in Huntington disease.

Gelareh Mazarei1, Scott J Neal, Kristina Becanovic, Ruth Luthi-Carter, Elizabeth M Simpson, Blair R Leavitt.   

Abstract

Selective degeneration of striatal neurons is a pathologic hallmark of Huntington disease (HD). The exact mechanism(s) behind this specific neurodegeneration is still unknown. Expression studies of diseased human post-mortem brain, as well as different mouse models exhibiting striatal degeneration, have demonstrated changes in the expression of many important genes with a large proportion of changes being observed in the striatal-enriched genes. These investigations have raised questions about how enrichment of particular transcripts in the striatum can lead to its selective vulnerability to neurodegeneration. Monitoring the expression changes of striatal-enriched genes during the course of the disease may be informative about their potential involvement in selective degeneration. In this study, we analyzed a Serial Analysis of Gene Expression (SAGE) database (www.mouseatlas.org) and compared the mouse striatum to 18 other brain regions to generate a novel list of striatal-enriched transcripts. These novel striatal-enriched transcripts were subsequently evaluated for expression changes in the YAC128 mouse model of HD, and differentially expressed transcripts were further examined in human post-mortem caudate samples. We identified transcripts with altered expression in YAC128 mice, which also showed consistent expression changes in human post-mortem tissue. The identification of novel striatal-enriched genes with altered expression in HD offers new avenues of study, leading towards a better understanding of specific pathways involved in the selective degeneration of striatal neurons in HD.

Entities:  

Mesh:

Year:  2009        PMID: 19934114      PMCID: PMC2807369          DOI: 10.1093/hmg/ddp527

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  38 in total

1.  Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice.

Authors:  J A Bibb; Z Yan; P Svenningsson; G L Snyder; V A Pieribone; A Horiuchi; A C Nairn; A Messer; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Quantitative assessment of transcriptome differences between brain territories.

Authors:  Michel de Chaldée; Marie-Claude Gaillard; Nicolas Bizat; Jean-Marie Buhler; Olivier Manzoni; Joël Bockaert; Philippe Hantraye; Emmanuel Brouillet; Jean-Marc Elalouf
Journal:  Genome Res       Date:  2003-07       Impact factor: 9.043

3.  Pyramidal cell loss in motor cortices in Huntington's disease.

Authors:  Virginia Macdonald; Glenda Halliday
Journal:  Neurobiol Dis       Date:  2002-08       Impact factor: 5.996

4.  Identification of a candidate tumor-suppressor gene specifically activated during Ras-induced senescence.

Authors:  Marta Barradas; Efstathios S Gonos; Zoë Zebedee; Evangelos Kolettas; Charikleia Petropoulou; M Dolores Delgado; Javier León; Eiji Hara; Manuel Serrano
Journal:  Exp Cell Res       Date:  2002-02-15       Impact factor: 3.905

5.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.

Authors:  R Luthi-Carter; A Strand; N L Peters; S M Solano; Z R Hollingsworth; A S Menon; A S Frey; B S Spektor; E B Penney; G Schilling; C A Ross; D R Borchelt; S J Tapscott; A B Young; J H Cha; J M Olson
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

6.  Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.

Authors:  Edmond Y W Chan; Ruth Luthi-Carter; Andrew Strand; Steven M Solano; Sarah A Hanson; Molly M DeJohn; Charles Kooperberg; Kathryn O Chase; Marian DiFiglia; Anne B Young; Blair R Leavitt; Jang-Ho J Cha; Neil Aronin; Michael R Hayden; James M Olson
Journal:  Hum Mol Genet       Date:  2002-08-15       Impact factor: 6.150

7.  Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.

Authors:  Elizabeth J Slow; Jeremy van Raamsdonk; Daniel Rogers; Sarah H Coleman; Rona K Graham; Yu Deng; Rosemary Oh; Nagat Bissada; Sazzad M Hossain; Yu-Zhou Yang; Xiao-Jiang Li; Elizabeth M Simpson; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2003-07-01       Impact factor: 6.150

8.  Predictors of neuropathological severity in 100 patients with Huntington's disease.

Authors:  Adam Rosenblatt; Margaret H Abbott; Lisa M Gourley; Juan C Troncoso; Russell L Margolis; Jason Brandt; Christopher A Ross
Journal:  Ann Neurol       Date:  2003-10       Impact factor: 10.422

9.  Disruption of AP1S1, causing a novel neurocutaneous syndrome, perturbs development of the skin and spinal cord.

Authors:  Alexandre Montpetit; Stéphanie Côté; Edna Brustein; Christian A Drouin; Line Lapointe; Michèle Boudreau; Caroline Meloche; Régen Drouin; Thomas J Hudson; Pierre Drapeau; Patrick Cossette
Journal:  PLoS Genet       Date:  2008-12-05       Impact factor: 5.917

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  18 in total

1.  In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.

Authors:  Elizabeth A Thomas; Giovanni Coppola; Bin Tang; Alexandre Kuhn; SoongHo Kim; Daniel H Geschwind; Timothy B Brown; Ruth Luthi-Carter; Michelle E Ehrlich
Journal:  Hum Mol Genet       Date:  2010-12-20       Impact factor: 6.150

2.  FACS-array-based cell purification yields a specific transcriptome of striatal medium spiny neurons in a murine Huntington disease model.

Authors:  Haruko Miyazaki; Tomoyuki Yamanaka; Fumitaka Oyama; Yoshihiro Kino; Masaru Kurosawa; Mizuki Yamada-Kurosawa; Risa Yamano; Tomomi Shimogori; Nobutaka Hattori; Nobuyuki Nukina
Journal:  J Biol Chem       Date:  2020-06-04       Impact factor: 5.157

Review 3.  Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis.

Authors:  C Y Daniel Lee; Jeffrey P Cantle; X William Yang
Journal:  FEBS J       Date:  2013-07-31       Impact factor: 5.542

Review 4.  Amyloid in neurodegenerative diseases: friend or foe?

Authors:  Katie J Wolfe; Douglas M Cyr
Journal:  Semin Cell Dev Biol       Date:  2011-03-31       Impact factor: 7.727

5.  Targeting the UPR transcription factor XBP1 protects against Huntington's disease through the regulation of FoxO1 and autophagy.

Authors:  Rene L Vidal; Alicia Figueroa; Felipe A Court; Peter Thielen; Claudia Molina; Craig Wirth; Benjamin Caballero; Roberta Kiffin; Juan Segura-Aguilar; Ana Maria Cuervo; Laurie H Glimcher; Claudio Hetz
Journal:  Hum Mol Genet       Date:  2012-02-14       Impact factor: 6.150

6.  The K63 deubiquitinase CYLD modulates autism-like behaviors and hippocampal plasticity by regulating autophagy and mTOR signaling.

Authors:  Elisa Colombo; Guilherme Horta; Mona K Roesler; Natascha Ihbe; Stuti Chhabra; Konstantin Radyushkin; Giovanni Di Liberto; Mario Kreutzfeldt; Sven Schumann; Jakob von Engelhardt; Doron Merkler; Christian Behl; Thomas Mittmann; Albrecht M Clement; Ari Waisman; Michael J Schmeisser
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-23       Impact factor: 11.205

7.  Advancing a High Throughput Glycotope-centric Glycomics Workflow Based on nanoLC-MS2-product Dependent-MS3 Analysis of Permethylated Glycans.

Authors:  Cheng-Te Hsiao; Po-Wei Wang; Hua-Chien Chang; Yen-Ying Chen; Shui-Hua Wang; Yijuang Chern; Kay-Hooi Khoo
Journal:  Mol Cell Proteomics       Date:  2017-10-24       Impact factor: 5.911

8.  Striatal Projection Neurons Require Huntingtin for Synaptic Connectivity and Survival.

Authors:  Caley J Burrus; Spencer U McKinstry; Namsoo Kim; M Ilcim Ozlu; Aditya V Santoki; Francia Y Fang; Annie Ma; Yonca B Karadeniz; Atesh K Worthington; Ioannis Dragatsis; Scott Zeitlin; Henry H Yin; Cagla Eroglu
Journal:  Cell Rep       Date:  2020-01-21       Impact factor: 9.423

Review 9.  The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease.

Authors:  Marta Amaral; Tiago F Outeiro; Nigel S Scrutton; Flaviano Giorgini
Journal:  J Mol Med (Berl)       Date:  2013-05-01       Impact factor: 4.599

10.  Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.

Authors:  Carlo Breda; Korrapati V Sathyasaikumar; Shama Sograte Idrissi; Francesca M Notarangelo; Jasper G Estranero; Gareth G L Moore; Edward W Green; Charalambos P Kyriacou; Robert Schwarcz; Flaviano Giorgini
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.